BridgeBio Pharma Inc’s recently made public that its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $3.08 million on Jan 09 ’26. In the deal valued at $77.11 per share,40,000 shares were sold. As a result of this transaction, Kumar Neil now holds 715,686 shares worth roughly $56.62 million.
Then, Kumar Neil sold 40,000 shares, generating $2,958,855 in total proceeds. Upon selling the shares at $73.97, the Chief Executive Officer now owns 735,686 shares.
Before that, KUMAR HALDEA REVOCABLE TRUST U bought 120,000 shares. BridgeBio Pharma Inc shares valued at $8,912,400 were divested by the Director at a price of $74.27 per share.
Morgan Stanley initiated its BridgeBio Pharma Inc [BBIO] rating to an Overweight in a research note published on January 06, 2026; the price target was $96. A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. Truist started covering the stock on July 21, 2025. It rated BBIO as “a Buy”.
Price Performance Review of BBIO
On Tuesday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 2.95% to $79.11. Over the last five days, the stock has gained 6.92%. BridgeBio Pharma Inc shares have risen nearly 172.04% since the year began. Nevertheless, the stocks have risen 3.43% over the past one year.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-12-31, dropping by -2.17 million shares to a total of 17.21 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 19.38 million shares. There was a decline of -12.61%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 14, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
